Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982985 | 0.79 | CYP3A4 (0.47) | — | |
| SCHEMBL496870 | 0.74 | MAPKAPK2 (0.36) | PKM | |
| SCHEMBL10535479 | 0.73 | MAPT (0.40) | PKM | |
| SCHEMBL11117589 | 0.73 | EGFR (0.34) | — | |
| SCHEMBL2423608 | 0.72 | LMNA (0.33) | — | |
| SCHEMBL1287815 | 0.71 | MCL1 (0.46) | — | |
| SCHEMBL9983598 | 0.71 | PKM (0.33) | PKM | |
| SCHEMBL9037556 | 0.71 | — | — | |
| SCHEMBL25278009 | 0.70 | KDM4E (0.50) | — | |
| SCHEMBL28216929 | 0.70 | TOP2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1694668-B1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | disclosed |
| EP-1699778-B1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-7652011-B2 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7423039-B2 | (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2007-02-15 | — | — | US | disclosed |
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1699778-A1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005054229-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | WO | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| US-5340808-A | Fused pyridazinoquinazolone derivatives as neurotrophic agents | WARNER LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5340808-A | Fused pyridazinoquinazolone derivatives as neurotrophic agents | WARNER LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1994011373-A1 | PYRIDAZINOQUINAZOLONE DERIVATIVES AS NEUROTROPHIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| US-4256483-A | 2-Alkoxy pyridazinoquinazolinone derivatives as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-03-17 | — | — | US | disclosed |
| US-4256483-A | 2-Alkoxy pyridazinoquinazolinone derivatives as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | TRPV1, IL1B, OPRK1 | PKM 851/4885 |
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | AQP4, AQP1, IL4I1 | PKM 350/4885 |
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | AGPAT5, DNPEP, AGPAT2 | PKM 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.